These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 9207936

  • 41. Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773.
    Carter GW, Bell RL, Marsh K, Lanni C, Awni WM, Bouska J, Stewart AO, Hansen R, Dubé L, Brooks DW.
    Ann N Y Acad Sci; 1994 Nov 15; 744():262-73. PubMed ID: 7825849
    [Abstract] [Full Text] [Related]

  • 42. Rationalization of physicochemical characters of 1,5-diarylpyrazole analogs as dual (COX-2/LOX-5) inhibitors: a QSAR approach.
    Revathi S, Gupta AK, Soni LK, Kavitha S, Wagh R, Kaskhedikar SG.
    J Pharm Biomed Anal; 2006 Sep 18; 42(2):283-9. PubMed ID: 16781106
    [Abstract] [Full Text] [Related]

  • 43. Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase.
    Rückle T, Biamonte M, Grippi-Vallotton T, Arkinstall S, Cambet Y, Camps M, Chabert C, Church DJ, Halazy S, Jiang X, Martinou I, Nichols A, Sauer W, Gotteland JP.
    J Med Chem; 2004 Dec 30; 47(27):6921-34. PubMed ID: 15615541
    [Abstract] [Full Text] [Related]

  • 44. TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.
    Underiner TL, Ruggeri B, Aimone L, Albom M, Angeles T, Chang H, Hudkins RL, Hunter K, Josef K, Robinson C, Weinberg L, Yang S, Zulli A.
    Bioorg Med Chem Lett; 2008 Apr 01; 18(7):2368-72. PubMed ID: 18343109
    [Abstract] [Full Text] [Related]

  • 45. Inhibition of proliferation of PC3 cells by the branched-chain fatty acid, 12-methyltetradecanoic acid, is associated with inhibition of 5-lipoxygenase.
    Yang P, Collin P, Madden T, Chan D, Sweeney-Gotsch B, McConkey D, Newman RA.
    Prostate; 2003 Jun 01; 55(4):281-91. PubMed ID: 12712407
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Stereochemical and steric control of the UDP-glucuronosyltransferase-catalyzed conjugation reaction: a rational approach for the design of inhibitors for the human UGT2B7.
    Bichlmaier I, Finel M, Sippl W, Yli-Kauhaluoma J.
    ChemMedChem; 2007 Dec 01; 2(12):1730-40. PubMed ID: 17943712
    [Abstract] [Full Text] [Related]

  • 48. Zinc(II)-mediated inhibition of a ribonuclease by an N-hydroxyurea nucleotide.
    Higgin JJ, Yakovlev GI, Mitkevich VA, Makarov AA, Raines RT.
    Bioorg Med Chem Lett; 2003 Feb 10; 13(3):409-12. PubMed ID: 12565940
    [Abstract] [Full Text] [Related]

  • 49. Correlation of log P with molecular connectivity in hydroxyureas: influence of conformational system on log P.
    Parker GR.
    J Pharm Sci; 1978 Apr 10; 67(4):513-6. PubMed ID: 641760
    [Abstract] [Full Text] [Related]

  • 50. Synthesis and structure-activity relationships of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives as 5-lipoxygenase inhibitors.
    Phillips OA, Bosso MA, Ezeamuzie CI.
    J Enzyme Inhib Med Chem; 2020 Dec 10; 35(1):1471-1482. PubMed ID: 32635785
    [Abstract] [Full Text] [Related]

  • 51. Discovery of a novel dual fungal CYP51/human 5-lipoxygenase inhibitor: implications for anti-fungal therapy.
    Hoobler EK, Rai G, Warrilow AG, Perry SC, Smyrniotis CJ, Jadhav A, Simeonov A, Parker JE, Kelly DE, Maloney DJ, Kelly SL, Holman TR.
    PLoS One; 2013 Dec 10; 8(6):e65928. PubMed ID: 23826084
    [Abstract] [Full Text] [Related]

  • 52. Novel NSAID 1-acyl-4-cycloalkyl/arylsemicarbazides and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides as potential anticancer agents and antioxidants.
    Perković I, Butula I, Kralj M, Martin-Kleiner I, Balzarini J, Hadjipavlou-Litina D, Katsori AM, Zorc B.
    Eur J Med Chem; 2012 May 10; 51():227-38. PubMed ID: 22405290
    [Abstract] [Full Text] [Related]

  • 53. Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase.
    Kenyon V, Rai G, Jadhav A, Schultz L, Armstrong M, Jameson JB, Perry S, Joshi N, Bougie JM, Leister W, Taylor-Fishwick DA, Nadler JL, Holinstat M, Simeonov A, Maloney DJ, Holman TR.
    J Med Chem; 2011 Aug 11; 54(15):5485-97. PubMed ID: 21739938
    [Abstract] [Full Text] [Related]

  • 54. Chiral spiroaminoborate ester as a highly enantioselective and efficient catalyst for the borane reduction of furyl, thiophene, chroman and thiochroman containing ketones.
    Stepanenko V, De Jesús M, Correa W, Bermúdez L, Vázquez C, Guzmán I, Ortiz-Marciales M.
    Tetrahedron Asymmetry; 2009 Dec 11; 20(23):2659-2665. PubMed ID: 20161579
    [Abstract] [Full Text] [Related]

  • 55. Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
    Stewart AO, Bhatia PA, Martin JG, Summers JB, Rodriques KE, Martin MB, Holms JH, Moore JL, Craig RA, Kolasa T, Ratajczyk JD, Mazdiyasni H, Kerdesky FA, DeNinno SL, Maki RG, Bouska JB, Young PR, Lanni C, Bell RL, Carter GW, Brooks CD.
    J Med Chem; 1997 Jun 20; 40(13):1955-68. PubMed ID: 9207936
    [Abstract] [Full Text] [Related]

  • 56. (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
    Brooks CD, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG, Craig RA, Kolasa T, Bouska JB, Lanni C.
    J Med Chem; 1995 Nov 24; 38(24):4768-75. PubMed ID: 7490726
    [Abstract] [Full Text] [Related]

  • 57. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents.
    Bell RL, Harris RR, Malo PE, Bouska JB, Shaughnessy TK, Hulkower KI, Brooks CD, Carter GW.
    J Pharmacol Exp Ther; 1997 Mar 24; 280(3):1366-73. PubMed ID: 9067325
    [Abstract] [Full Text] [Related]

  • 58. Structure-activity relationship for two lipoxygenase inhibitors and their potential for inducing nephrotic syndrome.
    Morley TJ, Evans GO, Goodwin DA, Read NG, Hodgson ST, Hawksworth GM.
    Toxicol Appl Pharmacol; 1997 Oct 24; 146(2):299-308. PubMed ID: 9344898
    [Abstract] [Full Text] [Related]

  • 59. Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
    Adams JL, Garigipati RS, Sorenson M, Schmidt SJ, Brian WR, Newton JF, Tyrrell KA, Garver E, Yodis LA, Chabot-Fletcher M, Tzimas M, Webb EF, Breton JJ, Griswold DE.
    J Med Chem; 1996 Dec 20; 39(26):5035-46. PubMed ID: 8978834
    [Abstract] [Full Text] [Related]

  • 60. Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
    Stewart AO, Bhatia PA, Martin JG, Summers JB, Rodriques KE, Martin MB, Holms JH, Moore JL, Craig RA, Kolasa T, Ratajczyk JD, Mazdiyasni H, Kerdesky FA, DeNinno SL, Maki RG, Bouska JB, Young PR, Lanni C, Bell RL, Carter GW, Brooks CD.
    J Med Chem; 1997 Jun 20; 40(13):1955-68. PubMed ID: 9207936
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.